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Abstract
Background In clinical practice, a2-adrenoceptor agonists
have been adjunctively administered with psychostimulants
for the treatment of attention-deficit/hyperactivity disorder
(ADHD). Two studies have examined the adjunctive use of
guanfacine extended release (GXR, Intuniv; Shire
Development LLC, Wayne, PA, USA) with psychostimu-
lants in children and adolescents with a suboptimal
response to psychostimulant treatment. However, the
potential for pharmacokinetic drug–drug interactions
(DDIs) between GXR and lisdexamfetamine dimesylate
(LDX, Vyvanse; Shire US LLC, Wayne, PA, USA) has
not been thoroughly evaluated.
Objective The primary objective of this study was to
examine the pharmacokinetics of GXR 4 mg and LDX
50 mg given as single doses alone and in combination.
Study Design This was an open-label, randomized, three-
period crossover, DDI study.
Setting The study was conducted in a single clinical
research center.
Participants Forty-two healthy adults were randomized
in this study.
Interventions Subjects were administered single oral
doses of GXR 4 mg, LDX 50 mg, or GXR and LDX in
combination.
Main Outcome Measures Blood samples collected pre-
dose and up to 72 h postdose assessed guanfacine, LDX, and
d-amphetamine levels. Bioequivalence was defined as the
90 % confidence intervals (CIs) of the geometric mean ratios
of the area under the plasma concentration–time curve
extrapolated to infinity (AUC0–?) and maximum plasma
concentration (Cmax) falling within the bioequivalence refer-
ence interval (0.80–1.25). Safety measures included adverse
events, vital signs, and electrocardiograms (ECGs).
Results Forty subjects completed the study. Following
administration of LDX alone or in combination with GXR,
the statistical comparisons of the AUC0–? and Cmax of d-
amphetamine fell entirely within the reference interval. For
guanfacine, the 90 % CI of the geometric mean ratio of
AUC? for the two treatments was within the bioequiva-
lence criteria, but for Cmax the upper bound of the 90 % CI
exceeded the standard range for bioequivalence by 7 %.
This relatively small change is unlikely to be clinically
meaningful. Treatment-emergent adverse events (TEAEs)
were reported by 42.9 % of subjects; the most commonly
reported TEAEs included dizziness (5.0, 7.3, and 7.3 %)
and headache (7.5, 4.9, and 7.3 %) following administra-
tion of GXR, LDX, and GXR and LDX in combination,
respectively. Clinically significant ECG abnormalities
occurred in one subject following administration of LDX
and in one subject following coadministration of GXR and
LDX.
Conclusions In healthy adults, coadministration of GXR
and LDX did not result in a clinically meaningful phar-
macokinetic DDI compared with either treatment alone. No
unique TEAEs were observed with coadministration of
GXR and LDX compared with either treatment alone.
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1 Introduction
In clinical practice, a2-adrenoceptor agonists have been
adjunctively administered with psychostimulants for the
treatment of attention-deficit/hyperactivity disorder
(ADHD) [1–4]. Guanfacine extended release (GXR;
Intuniv; Shire Development Inc., Wayne, PA, USA), a
selective a2A-adrenoceptor agonist [5], is approved by the
US Food and Drug Administration as monotherapy and as
adjunctive therapy to psychostimulant medications for the
treatment of ADHD in children and adolescents aged
6–17 years [5]. Treatment-emergent adverse events
(TEAEs) commonly reported with GXR monotherapy
treatment include somnolence, fatigue, nausea, lethargy,
and hypotension [6–10]. Patients taking GXR have dem-
onstrated similar growth compared with normative data [5].
Psychostimulants are the most widely prescribed phar-
macologic agents for the treatment of ADHD [11, 12].
Lisdexamfetamine dimesylate (LDX; Vyvanse; Shire US
LLC, Wayne, PA, USA) is a long-acting prodrug psycho-
stimulant, which is approved as monotherapy for the
treatment of ADHD in children (aged 6–12 years), in
adolescents (aged 13–17 years), and in adults [13]. TEAEs
commonly reported with LDX treatment across these
populations include anxiety, decreased appetite, diarrhea,
dry mouth, insomnia, irritability, nausea, upper abdominal
pain, and vomiting [13].
Two studies have examined the adjunctive use of GXR
with psychostimulants in children and adolescents with a
suboptimal response to psychostimulant treatment. An
open-label study found that the addition of GXR did not
result in unique adverse events (AEs) compared with those
reported historically with either treatment alone, and
adjunctive administration was also associated with signif-
icant improvements in ADHD symptoms [14]. The results
of this earlier study were confirmed in a large, pivotal,
multicenter, randomized, placebo-controlled study of GXR
adjunctive to psychostimulants [15]. Despite these earlier
investigations, the potential for pharmacokinetic drug–drug
interactions (DDIs) between GXR and LDX has not been
thoroughly evaluated.
Pharmacokinetic DDIs can occur when two medications
are coadministered, resulting in a change in the metabo-
lism, absorption, tissue and/or plasma binding, distribution,
or elimination of one or both medications [16]. Although
guanfacine is known to be metabolized by cytochrome
P450 (CYP) 3A4 [5], LDX is absorbed as the intact pro-
drug and is converted via enzymatic hydrolysis to l-lysine
and therapeutically active d-amphetamine primarily in the
blood by red blood cells [17]. Although intact LDX is not
metabolized by the CYP system and is neither an inducer
nor an inhibitor of the system, the metabolism of d-
amphetamine has not been fully characterized [13, 18]. It is
therefore prudent to study the pharmacokinetics of GXR
coadministered with LDX to confirm the lack of metabolic
interactions between these two therapies.
Although there is a lack of pharmacokinetic data on
coadministration of GXR and LDX, pharmacokinetic
studies of each medication administered alone have been
published [19–24]. An open-label, dose-escalation,
pharmacokinetic study of GXR in children (aged
6–12 years) and adolescents (aged 13–17 years) with
ADHD showed that GXR exhibits a linear pharmacoki-
netic profile [19]. A linear pharmacokinetic profile of
GXR was also observed in an open-label crossover study
examining single doses of GXR 1-, 2-, and 4-mg tablets
in healthy adults aged 18–55 years [20]. Maximum
guanfacine concentrations of 0.98, 1.57, and 3.58 ng/mL
were attained at 6 h for the 1- and 2-mg doses and at
5.5 h for 4-mg doses. When administered alone, LDX has
demonstrated a linear dose-proportional pharmacokinetic
profile in both children and adults [21, 22]. Maximum
mean d-amphetamine concentrations of 53.2, 93.3, and
134 ng/mL were attained in children with ADHD at 3.5 h
for the 30-, 50-, and 70-mg doses, respectively [21]. In
healthy adults, maximum mean d-amphetamine concen-
trations of 44.6, 84.6, and 126.6 ng/mL were attained at
4 h for the 50-, 100-, and 150-mg doses. For the 200- and
250-mg doses, maximum mean concentrations of 168.8
and 246.3 ng/mL, respectively, were attained at 6 h [22].
Two studies that assessed the pharmacokinetics of
LDX 70 mg in healthy adults found maximum mean
d-amphetamine concentrations of 80.3 and 90.1 ng/mL at
3 h [23, 24].
The safety profiles of GXR and LDX have been exam-
ined in previous studies. In subjects who received GXR in
clinical trials, systolic blood pressure (SBP), diastolic
blood pressure (DBP), and pulse rate decreased in a dose-
dependent manner [6, 7, 9]. Mean increases in SBP, DBP
(2–4 mmHg), and pulse rate (3–6 beats/min) are often
reported with LDX treatment [14, 25, 26].
The primary purpose of this present study was to eval-
uate the pharmacokinetic profiles of GXR and LDX,
administered alone and in combination, in healthy adults.
Evaluating the safety of GXR, LDX, and coadministered
GXR and LDX was a secondary objective of the study.
2 Materials and Methods
This was an open-label, randomized, three-period DDI
study of GXR and LDX in healthy adults aged
18–45 years. Written informed consent was obtained from
each subject, in accordance with the International Confer-
ence on Harmonisation (ICH) Good Clinical Practice
(GCP) Guideline E6 and applicable regulations.
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At screening, the inclusion criteria were a body mass
index between 20.0 and 30.0 kg/m2 (inclusive); a satis-
factory medical assessment with no significant or relevant
abnormalities in medical history, physical examination, or
vital signs; no laboratory evaluation that was considered
reasonably likely to interfere with the subject’s partici-
pation in or ability to complete the study; and normal or
clinically insignificant electrocardiogram (ECG) findings
at screening. Subjects were excluded from the study if
they had current or recurrent disease that could affect
clinical or laboratory assessments; a history of seizure
disorder; a history or presence of known cardiac abnor-
malities, syncope, cardiac conduction problems, exercise-
related cardiac events, or clinically significant bradycar-
dia; a history of controlled or uncontrolled hypertension
or a resting sitting SBP greater than 139 mmHg or DBP
greater than 89 mmHg; and symptomatic or clinically
meaningful orthostatic hypotension as assessed by the
investigator.
On day 1 of the first treatment period, subjects were
randomly assigned to one of the six possible treatment
sequences (i.e., ABC, ACB, BAC, BCA, CAB, CBA)
(Fig. 1). During each of the study’s three treatment periods,
subjects were administered one of three medication regi-
mens: regimen A consisted of a single 4-mg dose of GXR;
regimen B consisted of a single 50-mg dose of LDX;
regimen C consisted of coadministration of single doses of
GXR (4 mg) and LDX (50 mg). Subjects were confined to
the clinical research center during each treatment period
(i.e., from day -1 through day 4). The total confinement
for this study was 12 days. Washout periods of at least
7 days separated the treatment periods.
2.1 Pharmacokinetic Assessments
Guanfacine, lisdexamfetamine, and d-amphetamine levels
were measured in plasma produced from blood samples
collected at predose (within 30 min of administration) and
at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 12, 24, 30, 48, and
72 h after treatment. Blood samples were centrifuged at
approximately 2,500 rpm for 15 min at 4 C within 30 min
of the blood draw. Plasma concentrations were measured
using liquid chromatography (LC) with tandem mass
spectrometry (LC–MS/MS) methods that were validated
for the quantitation of guanfacine, lisdexamfetamine, and
d-amphetamine in human K3-EDTA plasma.
For guanfacine, the LC–MS/MS analysis was carried out
with a Sciex 4000 mass spectrometer coupled with a Shi-
madzu LC pump (model LC-10AT) and Perkin-Elmer 200
series autosampler. The internal standard used was guan-
facine (13C15N3). Guanfacine and its internal standard were
extracted from 200 lL of human plasma by liquid–liquid
extraction prior to LC–MS/MS analysis. The chromato-
graphic separation was achieved on an XBridge phenyl,
3.5 lm, 4.60 9 50 mm LC column (Waters Corporation),
with mobile phase at a flow rate of 1 mL/min. The mass
spectrometer was operated in positive electrospray ioniza-
tion mode, and the resolution settings used were unit for Q1
and low for Q3. The multiple reaction monitoring (MRM)
transition was m/z 246 ? 60 for guanfacine, and the MRM
transition was m/z 250 ? 159 for the internal standard,
guanfacine (13C15N3). On the basis of a sample volume of
200 lL, the assay ranged from 0.05 to 50 ng/mL for
guanfacine. Samples over the limit of quantitation were
diluted into range with control plasma.
For d-amphetamine and lisdexamfetamine, the LC–MS/
MS analysis was carried out with a Sciex API 3000 mass
spectrometer coupled with a Shimadzu LC pump (model
LC-10AT) and Perkin-Elmer 200 series autosampler. The
internal standards used were amphetamine-D5 for d-
amphetamine and lisdexamfetamine-D8 for lisdexamfeta-
mine. Plasma samples containing d-amphetamine, lis-
dexamfetamine, and their internal standards were extracted
by liquid–liquid extraction prior to the LC–MS/MS anal-
ysis. The chromatographic separation was achieved on a
Phenosphere NEXT CN, 5 lm, 4.6 9 50 mm column
(Phenomenex), with mobile phase at a flow rate of 1 mL/
min. The mass spectrometer was operated in positive
mode, and the resolution setting used was unit for both Q1
and Q3. The MRM transitions were m/z 136 ? 91 for d-
amphetamine, m/z 141 ? 96 for amphetamine-D5,
m/z 264 ? 84 for lisdexamfetamine, and m/z 272 ? 92
for lisdexamfetamine-D8. On the basis of a plasma sample
volume of 200 lL, the assay ranged from 2 to 200 ng/mL
for d-amphetamine and from 1 to 100 ng/mL for
lisdexamfetamine.
2.2 Safety Assessments
Safety evaluations included AEs, vital signs, 12-lead
ECGs, physical examination findings, and clinical labora-
tory parameters. Pulse and blood pressure (BP) were
assessed in both supine and standing positions predose
(within 30 min of administration) and at 1.0, 1.5, 2.0, 3.0,
4.0, 6.0, 8.0, 12, 24, 30, 48, and 72 h after treatment. ECGs
were recorded 2, 8, and 72 h after treatment was admin-
istered. TEAEs were defined as AEs that occurred or
worsened during the on-treatment period. TEAEs were
assigned to the treatment received at the time of onset of
the AE. Because this was a crossover study, a reported AE
was considered a TEAE for all periods of the crossover up
to 72 h after the last administration within each period,
unless a partial date or time showed that it was a TEAE that
occurred in an identified period.
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2.3 Statistical Analysis
The primary analysis was the pharmacokinetic analysis
performed using data from the pharmacokinetic population.
The pharmacokinetic population consisted of all subjects
who received at least one dose of the study medication, had
at least one postdose safety assessment, and had evaluable
concentration–time profiles for guanfacine, LDX, or d-
amphetamine.
Pharmacokinetic parameters were determined from the
plasma concentration–time data by noncompartmental
analysis and included the maximum plasma concentration
(Cmax), time to Cmax (tmax), area under the plasma con-
centration–time curve (AUC) to the last measurable con-
centration at time t (AUC0–t), AUC extrapolated to infinity
(AUC0–?), apparent terminal half-life (t1/2), apparent oral-
dose clearance (CL/F), and apparent volume of distribution
(Vz/F). CL/F and Vz/F were corrected for body weight.
Summary statistics, including the numbers of observa-
tions, means with standard deviations (SDs), coefficients of
variation, medians, maximums, minimums, and geometric
means were determined for all pharmacokinetic parameters
for all treatment regimens.
The means of log-transformed pharmacokinetic param-
eters were compared among (between) treatments using an
analysis of variance (ANOVA) with sequence, period, and
treatment as fixed effects and subject nested within
sequence as a random effect for a crossover study design.
To estimate the magnitude of the treatment differences in
Cmax and AUC0–?, the geometric mean ratio (GMR,
defined as the least squares mean difference in the log-
transformed parameters back-transformed to the original
scale) and their 90 % confidence intervals (CIs) were also
calculated.
If the 90 % CIs of the GMR ([GXR ? LDX]/GXR or
[GXR ? LDX]/LDX) of guanfacine or LDX following
coadministration of GXR and LDX to the same analyte
following GXR or LDX alone were to fall within the ref-
erence interval (0.80–1.25), then the hypothesis of a DDI of
GXR and LDX would be rejected. If the CIs were not
entirely contained within this interval, then the clinical
significance of such mean ratio estimates and confidence
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Regimen B: LDX 50 mg
Regimen C: GXR + LDX
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limits would be interpreted within the context of the ther-
apeutic index.
The available within-subject estimates of the SDs of the
log-transformed parameters AUC0–? (SD = 0.26) and
Cmax (SD = 0.31) for GXR were pooled from previous
studies of GXR. A previous study of LDX reported a
within-subject SD for log-transformed parameters of 0.215
for Cmax and 0.195 for AUC0–? [22]. A total of 36 subjects
(six per sequence) were required to demonstrate equiva-
lence, using the bioequivalence reference interval
(0.80–1.25), allowing for a 5 % difference between treat-
ment means, to achieve 90 % power.
3 Results
3.1 Subject Disposition and Demographics
Forty-two subjects were randomized, and 40 (95.2 %)
completed the study. No subjects withdrew because of an
AE. Early terminations included one withdrawal by a
subject and one withdrawal by the primary investigator
prior to administration of GXR alone, because of poor
tolerance of coadministered GXR and LDX. Demographic
and baseline characteristics are summarized in Table 1.
3.2 Pharmacokinetic Results
A summary of the pharmacokinetic parameters of guanfa-
cine and d-amphetamine following administration of GXR
alone, LDX alone, and GXR and LDX in combination is
presented in Table 2.
3.2.1 Results for Guanfacine
The mean guanfacine plasma concentration following
administration of GXR alone was slightly lower than the
mean guanfacine concentration following coadministration
with LDX (Fig. 2). Maximum plasma concentrations of
guanfacine were attained at a median of 6 h after admin-
istration of GXR alone or in combination with LDX. The
90 % CI of the GMR of AUC0–? for guanfacine following
GXR administered alone and in combination with LDX
was 0.981–1.162 and met strict bioequivalence criteria
requiring 90 % CIs to fall within the interval of 0.80–1.25.
The 90 % CI of the GMR of Cmax for guanfacine following
administration of GXR alone and in combination with
LDX was 1.066–1.321 and did not fall within the standard
bioequivalence reference interval. The upper bound of the
90 % CI of Cmax for guanfacine exceeded the standard
range for bioequivalence by 7 % when GXR was coad-
ministered with LDX.
3.2.2 Results for d-Amphetamine and Lisdexamfetamine
The mean d-amphetamine plasma concentrations following
administration of LDX alone were essentially identical to
those following coadministration with GXR (Fig. 3a).
Maximum plasma concentrations of d-amphetamine were
attained at a median of 4 h following dosing of LDX alone
or in combination with GXR. The 90 % CIs of the GMRs
for Cmax and AUC0–? for d-amphetamine following
administration of LDX alone and in combination with
GXR (0.967–1.019 and 0.983–1.06, respectively) met strict
bioequivalence criteria requiring 90 % CIs to fall within
the interval of 0.80–1.25.
Similar profiles for mean plasma LDX concentrations
were obtained for regimen B (LDX alone) and regimen C
(LDX and GXR) (Fig. 3b). When LDX was given alone
and in combination with GXR, its mean maximum con-
centrations were 26.14 and 27.13 ng/mL, respectively, and
were obtained at 1.1 h.
Table 1 Summary of demographic and baseline characteristics of the
study population (N = 42)a
Characteristic Value
Age (years)
Mean [SD] 30.5 [7.41]
Median 28.5





Mean [SD] 78.2 [11.20]
Median 75.6
Minimum, maximum 54, 101
Height (cm)
Mean [SD] 173.8 [8.76]
Median 175.5
Minimum, maximum 157, 189
Body mass index (kg/m2)
Mean [SD] 25.8 [2.55]
Median 25.9
Minimum, maximum 21, 30
Ethnicity (n [%])
Hispanic or Latino 12 [28.6]
Not Hispanic or Latino 30 [71.4]
Race (n [%])
White 15 [35.7]
Black or African American 27 [64.3]
SD standard deviation
a Percentages are based on the number of subjects in the safety
population and in each randomized treatment sequence
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3.3 Safety Results
3.3.1 Treatment-Emergent Adverse Events
A total of 18 subjects (42.9 %) reported at least one TEAE.
TEAEs were reported in seven subjects (17.5 %), eight
subjects (19.5 %), and 10 subjects (24.4 %) while they
were receiving GXR, LDX, and GXR and LDX in com-
bination, respectively. The most commonly reported indi-
vidual TEAEs (occurring in C5 % of subjects during any
regimen) were dizziness (5.0, 7.3, and 7.3 %), postural
dizziness (10.0, 2.4, and 0 %), and headache (7.5, 4.9, and
Table 2 Pharmacokinetic parameters of guanfacine and d-amphetamine
Parameter Cmax (ng/mL) tmax (h) AUC0–? (ngh/mL) t1/2 (h) CL/F (L/h/kg) Vz/F (L/kg)
Summary of guanfacine pharmacokinetic parameters
GXR alone
N 40 40 37 37 37 37
Mean [SD] 2.55 [1.03] 8.6 [7.7] 104.9 [34.7] 23.5 [10.2] 0.54 [0.17] 17.36 [7.54]
Median 2.30 6 102.4 20.5 0.51 15.34
Minimum, maximum 0.98, 5.79 1.5, 30 54, 218.2 11.4, 50 0.27, 1.04 7.02, 38.05
GXR ? LDX
N 41 41 39 39 39 39
Mean [SD] 2.97 [0.98] 7.9 [5] 112.8 [35.7] 21.4 [8.2] 0.5 [0.15] 15.33 [7.35]
Median 2.87 6 109.4 18.8 0.46 13.61
Minimum, maximum 1.52, 5.60 3, 30 61.5, 213.6 11.9, 48.2 0.3, 0.89 6.36, 44.79
Summary of d-amphetamine pharmacokinetic parameters
LDX alone
N 41 41 41 41 41 41
Mean [SD] 36.48 [7.13] 4.2 [1.1] 686.9 [159.8] 11.2 [1.6] 0.99 [0.23] 15.58 [2.52]
Median 36.95 4 687.7 11.3 0.93 15.33
Minimum, maximum 20.51, 57.15 3, 6 324.6, 1070 8.3, 14.6 0.66, 1.8 11.16, 21.77
GXR ? LDX
N 41 41 41 41 41 41
Mean [SD] 36.50 [6.00] 3.9 [1.1] 708.4 [137.8] 11.2 [1.5] 0.95 [0.17] 15.11 [2.37]
Median 35.71 4 713.6 11 0.95 14.43
Minimum, maximum 23.05, 53.06 3, 8 456.1, 954.1 8, 15.1 0.67, 1.34 11.45, 23.8
AUC0–? area under the plasma concentration–time curve extrapolated to infinity, CL/F apparent oral-dose clearance, Cmax maximum plasma
concentration, GXR guanfacine extended release, LDX lisdexamfetamine dimesylate, SD standard deviation, t1/2 apparent terminal half-life, tmax





















Fig. 2 Mean guanfacine
plasma concentrations over time
following administration of
guanfacine extended release
(GXR) alone and in
combination with
lisdexamfetamine dimesylate
(LDX). A time shift has been
applied to the figure; values
have been slightly staggered on
the x-axis for clarity, as some
values were similar between the
two treatment regimens
124 B. Roesch et al.
7.3 %) following administration of GXR, LDX, and GXR
and LDX in combination, respectively. Most TEAEs were
mild. No discontinuations were due to TEAEs.
3.3.2 Vital Signs
The supine pulse rate, SBP, and DBP following adminis-
tration of GXR alone and LDX alone were similar to those
previously observed for either drug. Following adminis-
tration of GXR alone, there was a modest decrease in pulse
rate, which began to return toward predose levels after hour
6. Supine SBP and DBP were modestly decreased across
the 12-h period. Following administration of LDX alone,
there was a modest increase in pulse rate, as well as
increases in supine SBP and DBP.
Coadministration of LDX and GXR yielded results
similar to those seen with LDX administered alone, such
that a modest increase in supine pulse rate, as well as
increases in SBP and DBP, was observed following coad-
ministration (Figs. 4, 5). There did not appear to be
clinically important differences in postural orthostatic
changes (i.e., differences between standing and supine
parameters) in pulse rate or in BP following coadminis-
tration of GXR and LDX compared with GXR alone.
3.3.3 Electrocardiogram Results
Overall, clinically meaningful changes in ECGs were not
observed, and the ECG results for GXR alone and LDX
alone were consistent with the known effects of these
medications. Two subjects had clinically significant
abnormalities in ECG results. One subject had a wandering
atrial pacemaker 2 h after administration of LDX. The
subject was asymptomatic, and the event was considered
mild and resolved the same day. The other subject had a
supraventricular arrhythmia (first-degree atrioventricular
block [pulse rate interval = 204 ms] with bradycardia
[45 beats/min] and escape beats) 2 h after coadministra-
tion. The subject was asymptomatic, and the event was




































LDX alone and in combination
with guanfacine extended
release (GXR). A time shift has
been applied to the figure;
values have been slightly
staggered on the x-axes for
clarity, as some values were
similar between the two
treatment regimens
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4 Discussion
Guanfacine is known to be metabolized by CYP3A4 [5].
While intact LDX is not metabolized by the CYP system
and is neither an inducer nor an inhibitor of the system, the
metabolism of amphetamine has not been fully elucidated
[18]. Data have suggested that CYP2D6 is involved in the
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Fig. 4 Mean (±standard
deviation) supine pulse rate over
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Fig. 5 a Mean (±standard
deviation [SD]) supine systolic
blood pressure (SBP) and
b mean (±SD) supine diastolic
blood pressure (DBP) over
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suggested that amphetamine and its metabolites inhibit
CYP2D6, CYP1A2, and CYP3A4 enzymes [13, 18, 27–
29]. Therefore, it was prudent to evaluate the pharmaco-
kinetics of GXR coadministered with LDX to confirm a
lack of metabolic interactions between these two medica-
tions, as GXR is likely to be adjunctively administered
with psychostimulants such as LDX to treat ADHD.
Although the guanfacine Cmax exceeded the standard
upper limit of bioequivalence by 7 % when GXR was
coadministered with LDX, overall, coadministration of
GXR and LDX did not result in a clinically meaningful
pharmacokinetic DDI compared with the pharmacokinetics
of either treatment administered alone. The 90 % CIs of the
GMRs for AUCt and AUC0–? for guanfacine following
administration of GXR alone and in combination with
LDX fell within the reference interval (0.80–1.25). The
guanfacine Cmax was increased by 19 % when GXR was
coadministered with LDX. The 90 % CIs of the GMRs for
Cmax, AUCt, and AUC0–? for d-amphetamine following
administration of LDX alone and in combination with
GXR fell entirely within the reference interval (0.80–1.25).
The TEAEs reported in this study were expected and
were consistent with those observed historically with psy-
chostimulants administered alone or with GXR [5–7, 30,
31]. No differences in the type, incidence, or severity of
TEAEs among treatment groups were observed, and no
subject discontinued treatment because of an AE. In
addition, no clinically meaningful changes in ECGs, clin-
ical laboratory parameters, or physical examinations were
noted during the study.
4.1 Study Limitations
The results of this small open-label study, conducted in a
medically healthy adult population, should be viewed with
consideration of several limitations. As GXR is approved
for the treatment of ADHD in children and adolescents
aged 6–17 years [5], the healthy adult subjects in this study
may not have been representative of the population com-
monly treated with this medication in a clinical setting. In
addition to age considerations, more studies would be
needed to determine if similar outcomes would be seen in
populations likely to receive adjunctive administration in
clinical practice (e.g., subjects with comorbid disorders). In
addition, subjects with comorbidities that may contribute to
cardiac AEs were excluded from the study.
Caution should also be used in interpreting these results,
as this study was designed to assess the pharmacokinetic
parameters of coadministration of GXR and LDX; the
study was not designed to robustly assess the cardiovas-
cular effects of coadministration. As this was a single-dose
rather than multiple-dose study, the effects that were
observed may not be representative of those occurring at
steady state. Therefore, the findings of this study may not
be readily extrapolated to the therapeutic setting.
Finally, it is not known if similar safety and cardio-
vascular effects would be seen in large, randomized, dou-
ble-blind, placebo-controlled studies, or in studies that
assessed coadministration of GXR and LDX over a longer
time period. Future studies should examine these areas, as
well as the efficacy of coadministration.
5 Conclusions
Overall, coadministration of GXR and LDX did not result
in a clinically meaningful pharmacokinetic DDI compared
with the pharmacokinetics of either treatment administered
alone. No unique TEAEs were observed with coadminis-
tration of GXR and LDX compared with either treatment
alone. However, as the study was not designed to robustly
assess cardiovascular effects and other safety parameters,
further study of the safety of coadministration of GXR and
psychostimulants is warranted.
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